




Scientific Discovery: From the Lab Bench to the GPU

Michelle L. Gill, PhD; Tech Lead and R&D Manager, NVIDIA

PyDataNYC | 3rd November, 2023



Motivation: Drug Development is a Long and Expensive Process



\$2.8B and >10 Years to Bring a Drug to Market

Language Models are Revolutionizing Discovery


- Information from biomedical literature
- Prediction of chemical reactions
- Biomolecular property prediction
- Structure prediction and docking




BIOMEDICAL NLP
Learn all of PubMed



GENERATIVE CHEMISTRY
Novel Drug Candidates




PROTEIN STRUCTURE
Predict 3D Structures



VIRTUAL SCREENING
Docking and Pose Prediction

From Sequence to 3D and Back Again



Outline


- Overview of BioNeMo: Inference Service and Training Framework
- MolMIM: Development of a Small Molecule Foundation Model for Generation
- Career Progression and Lessons from the Field

The background of the slide is a black field filled with abstract, glowing green elements. On the left, there are numerous thin, parallel lines of varying lengths and slight curves, creating a sense of motion or data flow. On the right side, there are more complex, overlapping green structures that resemble stylized, translucent leaves or perhaps a network of interconnected nodes and edges, giving it a biological or technological feel.

BioNeMo Overview: Inference Service and Framework


NVIDIA BioNeMo

AI Tools, Frameworks, and Applications for Drug Discovery




Multiple Interfaces to a BioNeMo Model in the Inference Service

Interactive UI and Jupyter Workflows



API and Python Client



Welcome to BioNeMo!

Get started with a model below. Explore documentation for more information.

[Secondary Action](#)
[Primary Action](#)

Get Started with BioNeMo



Protein Generation

These models generate proteins with a sequence distribution that mirrors the distribution of proteins on which the model was trained.

[ProtGPT-2](#)


Protein Embedding

These models generate protein embeddings. They take an amino acid sequence and returns a learned representation.

[ESM-1nv](#)
[ESM-2](#)


Molecule Generation

Given a seed molecule, these models can generate similar molecules

[MoFlow](#)
[MegaMolBART](#)


Molecule Embedding

These models generate embeddings for a given molecule.

[MegaMolBART](#)


Protein Folding

These models predict the 3D structure of a protein from only the sequence of amino acids.

[ESMFold](#)
[OpenFold](#)
[AlphaFold-2](#)


Docking

These models take a molecule structure and a protein structure and predict the docked pose.

[DiffDock](#)


Generate an API Key

Authenticate your identity while making queries to NeMo LLM via the REST API.

[Generate API Key](#)


Documentation

Learn more about using NeMo LLM and dive deep with tutorials, how-to guides and examples.

[Documentation](#)

Playground

Protein Generation Protein Embedding Molecule Generation Molecule Embedding **Protein Folding** Docking

Choose a model to generate sequence output. If you have a Compound CID, input it below or you can start with one of our provided example use cases.

Model
OpenFold

Enter a PDB ID
Enter PDB ID... Look Up

Or
Select an Example PDB ID
Select an example PDB ID...

Input
MNI FEMLRIDEGLRLKIYKDTGGYYTIGIGHLT
KSPSLNAAAKSELDKAIGRNTNGVITKDEAEK
LFNQDVDAAVRGILRNAKLPYDSLDAVRR
AALINMVFMGETGVAGFTNSLRMLQQKRW
DEAAVNLAHSRWYNQTPNRAK...

MSA Options


No MSA will be generated. We recommend **uploading an MSA** for better results.

Output 1 of 40

Sequence of 7WZF | Struc... Chain 1: YunM A

```

MASDGGKAJSFLGKMAKMFGLKANDFLKGAJAHSGDFJSA GFHJDQJHSHJDHJHJHJJJJHGAHSDGGHSHGJHFGASJHDG FJAKHS GFJHJHAGSJHSDASJLDHALSJNJAHAH
161 111 121 131 141 151 161 171 181 191 201
ASKDJGAKSNVKASJDFNVAUSNRIAVNRVAKJRNAEURNANDSNALSKDNGALSNFVADJFNVA FVARNVARNVAVLKNFVALDFNVAKLDNFGLAKSDFNGLAKNUYERBVADYFBAHJHJHJHSDHF
211 221 231 241
MASDGGKAJSFLGKMAKMFGLKANDFLKGAJAHSGDFJSA G
  
```



Structure

7WZF | Structural and mechanism a...

Type	Assembly
Asm ID	1: Author Defined Asse...
Dynamic Bonds	Off

Nothing Focused

Measurements

Structure Motif Search

Components 7WZF

Preset	+ Add		
Asm ID	Cartoon	👁	🗑
Ligand	Ball & Stick	👁	🗑
Water	Ball & Stick	👁	🗑

Unit Cell P 63 2 2

Density

Quality Assessment

Assembly Symmetry

Export Models

Export Animation

Export Geometry

Clear Generate

Outputs displayed here are not saved. Download the output if you would like to keep it. [Learn more.](#)

Give Feedback

View Code

Expand

Download

Lab

Protein Generation Protein Embedding Molecule Generation Molecule Embedding **Protein Folding** Docking

Choose a model to generate sequence output. If you have a PDB ID, input it below or you can start with one of our provided example use cases.

Model ⓘ

OpenFold

Enter a UniProt ID ⓘ

Enter UniProt ID...

Look Up

Or

Select an Example UniProt ID ⓘ

Select an example UniProt ID...

Protein Sequence ⓘ

Look up a UniProt ID, choose an Example from the provided list or enter your own here...

Perform MD Refinement ⓘ

Brief description of what this does



MSA ⓘ

Upload an MSA or choose no MSA. One will be auto-generated if you take no action.

Choose MSA Option

Output ⓘ

View Code

OpenAPI ✕

Curl Python

```
1 curl -X POST "https://api.bionemo.ngc.nvidia.com/v1/protein-structure/openfold/predict" \
2   -H "Content-Type: application/json" \
3   -H "Authorization: Bearer $YOUR_NGC_API_TOKEN" \
4   -d '{
5     "sequence":
6     "MSFSGKYQLQSQENFEAFMKAIGLPEELIQGKDKGVSEIVQNGKHKFTITAGSKVIQNEFTVGEECELETMTGEKVKTVVQLEGDNKLVTTFKNIK
SVTELNGLDIITNTMTLGDIVFKRISKRI"
7   }'
```

Learn how to integrate the API into your application [here](#)
Click [here](#) to generate a new API key.

Copy Code

Done

Clear

Generate

Give Feedback

View Code

Download

Playground

Protein Generation Protein Embedding **Molecule Generation** Molecule Embedding Protein Folding Docking

Choose a model to generate molecules. If you have a Chemical CID, input it below or you can start with one of our provided example use cases.

 Learn More

Model ⓘ

MoFlow | v

Select an Example CID ⓘ

Look Up ID

Examples

Dicloxacillin | v

SMILES ⓘ

73 of 510 chars

Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N(C@@H)1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O


Number of Molecules ⓘ

20

Sample Temperature ⓘ

0.20  0.35

Output ⓘ



Clear

Generate

 Give Feedback

 View Code

 Download

Playground

Protein Generation Protein Embedding Molecule Generation Molecule Embedding Protein Folding Docking

Choose a model to generate docking poses. Provide a molecule and a target protein file.

 Learn More

Model ①

DiffDock | v

Molecule ①

 Ersitrelvir_analog x 

Target Protein ①

 SARS_CoV_2_MPro x 

Generated Poses ①

 20


Diffusion Steps ①

 18

Diffusion Time Divisions ①

 20

Output ①



 Center Pose  Reset View

☐ View All Poses < >

☒ Rank: 1 Score: -0.567

☐ Rank: 2 Score: -0.769

☐ Rank: 3 Score: -0.789

☐ Rank: 4 Score: -1.155

☐ Rank: 5 Score: -1.254

☐ Rank: 6 Score: -1.621

☐ Rank: 7 Score: -1.655

☐ Rank: 8 Score: -2.039

☐ Rank: 9 Score: -2.144

☐ Rank: 10 Score: -2.184

☐ Rank: 11 Score: -2.372

☐ Rank: 12 Score: -2.576

☐ Rank: 13 Score: -2.600

Clear


Generate

 Give Feedback

 View Code


 Download

BioNeMo Framework Overview




- Includes dataset processing, training, fine tuning, and example downstream tasks
- Support for multi-GPU and multi-node training
- Data parallelism, and three types of model parallelism
- Currently three LLM models for cheminformatics and protein applications – more models and model types coming soon

BioNeMo Framework Technology Stack




- Based on NVIDIA NeMo, which is a library for development and training of LLMs
- Automated deployment with Triton is in progress
- Surface and develop new software and hardware technology



MolMIM: Development of a Small Molecule Foundation Model for Generation

Motivation: Drug Development is a Long and Expensive Process




\$2.8B and >10 Years to Bring a Drug to Market

Lead Discovery: Three Years for Design-Make-Test-Analyze Cycle

Hit Compound

Known or experimentally determined
Weakly active
Target unselective
Toxicity risk
Low metabolic stability



Candidate Drug


Highly potent
Effective for *in vivo* models
Metabolically stable
No toxicity issues



Multiple of DMTA cycles at 4-6 weeks/cycle
Transition between multiple labs


Autoencoder Models in a Nutshell

Autoencoder




Also works
with
sequences --
seq2seq
models

Variational
Autoencoder (VAE)




Cheminformatics Foundation Model Objectives


Representation and Translation



Generation




SMILES: a Natural Language Representation of Small Molecules



COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c


MegaMolBART Molecule Representations

- MegaMolBART is a sequence-to-sequence developed in collaboration with AstraZeneca
- Based on BART NLP model
- Trained on 1.5B small molecules in SMILES format
- Useful for representation and sequence translation tasks
- Not well suited for generation tasks -- lacks an organized and uniformly shaped latent space




Autoencoder Models in a Nutshell


Autoencoder



Variational
Autoencoder (VAE)





Development of MolMIM for Molecule Generation




A Clustered Latent Space with Mutual Information Machine

- Mutual information machine (MIM) has a loss function that maximizes mutual information and minimizes marginal entropy
- MIM loss results in a clustered space while variational autoencoder (VAE) loss smooths the latent space resulting in blurring




MolMIM – Sampling Distance Can Be Tuned for Similarity


Small Perturbations



Larger Perturbations




Similarity Map



Measuring the Controllability of MolMIM Generation

- **Hypothesis:** having a structured latent space will improve performance of property guided optimization
- Chose covariance matrix adaptation (CMA-ES), which is a zeroth order optimization method
- CMA-ES is non-parametric and uses only a single scoring function per sample





Multi-Objective Property Optimization


- Performed multi-objective optimization to jointly optimize two molecule properties (QED, SA) and binding to two protein targets (JNK3, GSK4 β)
- Novelty is proportion of molecules with similarity metric (0.0 – 1.0) less than ≤ 0.4 relative to any other molecule
- Diversity is average similarity across all compounds
- MolMIM is competitive for success and diversity, but novelty has room for improvement

Model	QED + SA + JNK3 + GSK4 β		
	Success (%)	Novelty (%)	Diversity
RationaleRL	74.8	56.1	0.621
MARS	92.3	82.4	0.719
JANUS	100	32.6	0.821
FaST	100	100	0.716
MolMIM (R)	97.5	71.1	0.791
MolMIM (A)	96.6	63.3	0.807
MolMIM (E)	98.3	55.1	0.767
MolMIM (E) [†]	99.2	54.8	0.772

MolMIM: Research to Productization




- Integration of MolMIM model into BioNeMo inference service
- Productionize model architecture and training framework
- Accelerated inference
- Improving encoder representations

The background features a black field with numerous thin, bright green lines that create a sense of motion and depth. Some lines are straight and parallel, while others are curved and layered, giving the impression of a 3D space. On the far left, there is a solid, vertical green bar. The text is positioned on the left side, overlapping the black background and the green bar.


“How I Got Here” and Lessons Learned Along the Way

From Structural Biologist to Data Scientist

Postdoctoral Research: Enzyme Dynamics by
NMR Spectroscopy



AlexNet Won ImageNet Challenge in 2012




AlexNet didn't just win; it dominated. AlexNet was unlike the other competitors. This new model demonstrated unparalleled performance on the largest image dataset of the time, ImageNet. This event made AlexNet the first widely acknowledged, successful application of deep learning.

Don't miss the bigger picture: Machine learning will have an impact on every industry.

From Structural Biologist to Data Scientist

coursera

edX




 **PyData**
NYC 2013

 **nVIDIA®**

A Deep Learning Model Became the World's Best Protein Structure Predictor





...MALKIPTHNHM...
...VFRDCEWS...
...WYIOPMNVGTDEW...



Sequence

Structure




CASP15: AlphaFold's success spurs new challenges in ...

Dec 14, 2022 — Two years later, **AlphaFold** still **dominates** the competition. Deepmind itself did not participate in this round, but **AlphaFold** has been open ...

AlphaFold won the Critical Assessment of Protein Structure Prediction (CASP13) Competition in 2018 ... and has done so every year since

AI and the Race for a COVID-19 Vaccine




MIT Technology Review

ARTIFICIAL INTELLIGENCE

I Was There When: AI helped create a vaccine


August 26, 2022



Genome-scale language models (GenSLMs) discover distinct evolutionary patterns in SARS-CoV-2




First Effort: Interface for Clustering and Visualization of Small Molecules



RAPIDS





Deep learning is high risk. Ensure the project will succeed if deep learning fails.

The background of the slide features a faint, light gray outline map of Europe. Overlaid on this map are several thin, black line drawings of protein structures, including alpha-helices, beta-sheets, and various folded domains, scattered across the continent.


PROTEIN DESIGN

... by the time you've read this sentence, a new pre-print revolutionizing the field has been posted and these slides are totally outdated





Developing Deep Learning Models at Scale




Model Size (Param)	Training Time (Days)	
	512 x V100s	512 x A100s
650M	8	???
3B	30	




Successes from calculated risks provide justification for growing a team.

Rapid Team Growth and Adventures in Management



Two Engineers



< Two Years



Over Thirty Engineers

Deep learning is hard, but growing and managing a team is the most challenging problem.

Conclusions

- BioNeMo is a framework and inference service for developing, training, deploying, and using deep learning models and tools for drug discovery
- MolMIM is a cheminformatics language model trained on SMILES with a structured latent space for molecule design
- Careers are long compared to the pace of machine learning advancement
- Capitalize on new opportunities and enjoy the ride!

BioNeMo Inference Service early access : <https://www.nvidia.com/bionemo>

BioNeMo Framework general access coming next week!

The BioNeMo Team

Johnny Israeli

Gagan Kaushik

Ohad Mosafi

George Armstrong

Pablo Ribalta

Alireza Moradzadeh

Guoqing Zhou

Rajesh Ilango

Arkadiusz Nowaczynski

Han-Yi Chou

Sara Rabhi

Camir Ricketts

Jasleen Grewal

Simon Chu

Danny Reidenbach

Kevin Boyd

Srimukh Veccham

Dejun Lin

Maria Korshunova

Steven Kothen-Hill

Dorota Toczydlowska

Mario Geiger

Tomasz Grzegorzek

Emine Kucukbenli

Marta Stepniewska-Dziubinska

Timur Rvachov

Eric Dawson

Micha Livne

Yuxing Peng

Farhad Ramezanghorbani

Neha Tadimeti

Zachary McClure

Thank You!

Questions:

Fireside Chat

10:15 – 10:55am

Central Park East




mgill@nvidia.com




michellelynngill.com


Appendix



Nine Models in Inference Service for Drug Discovery Applications



Deep Learning at Scale



Attention Heads	Layers	Hidden Size	Feed Forward	Parameters
8	4	256	1024	10M
8	6	512	2048	45M
16	8	1024	4096	230M





Life Cycle of a BioNeMo Model in the Inference Service

- Model checkpoints are accelerated using a variety of NVIDIA tools – standard tricks to custom CUDA kernels
- All quantitative and qualitative results are reproduced
- For DiffDock, the RMSD metrics were reproduced under a variety of different conditions

Method	Holo crystal proteins			
	Top-1 RMSD		Top-5 RMSD	
	%<2	Med.	%<2	Med.
GNINA	22.9	7.7	32.9	4.5
SMINA	18.7	7.1	29.3	4.6
GLIDE	21.8	9.3	-	-
EQUIBIND	5.5	6.2	-	-
TANKBIND	20.4	4.0	24.5	3.4
P2RANK+SMINA	20.4	6.9	33.2	4.4
P2RANK+GNINA	28.8	5.5	38.3	3.4
EQUIBIND+SMINA	23.2	6.5	38.6	3.4
EQUIBIND+GNINA	28.8	4.9	39.1	3.1
DiffDock (10)	35.0	3.6	40.7	2.65
DiffDock (40)	38.2	3.3	44.7	2.40

NV Trial #1	38.0
NV Trial #2	35.0
NV Trial #3	38.6
NV Trial #4	39.1
NV Trial #5	38.6



Proteins Generated from Evozyne's ProT-VAE Models

ProT-VAE: Protein Transformer Variational AutoEncoder for Functional Protein Design



Emre Sevgen^{1†}, Joshua Moller^{1†}, Adrian Lange¹, John Parker¹, Sean Quigley¹, Jeff Mayer¹, Poonam Srivastava¹, Sitaram Gayatri¹, David Hosfield¹, Maria Korshunova², Micha Livne², Michelle Gill², Rama Ranganathan¹, Anthony B. Costa^{2*} and Andrew L. Ferguson^{1*}

¹Evozyne, Inc., 2430 N Halsted Street, Chicago, 60614, IL, USA.


²NVIDIA, 2788 San Tomas Expressway, Santa Clara, 95051, CA, USA.

*Corresponding author(s). E-mail(s): acosta@nvidia.com; andrew.ferguson@evozyne.com;

[†]These authors contributed equally to this work.



Probing Latent Structure by Molecule Interpolation



- Pairwise interpolations performed at ten evenly spaced steps for 1,000 ZINC15 molecules
- Average Tanimoto similarity to first molecule was calculated at each step
- Molecules sampled from Perceiver BART and MolVAE have reduced similarity to start and a large degree of variability at early interpolation steps
- Molecules sampled from MolMIM are similar and have the smallest variance at early steps

MolMIM – Performance on Seed Based Molecule Sampling

- Randomly sampled ten molecules for each of 20k molecules from test split
- Effective novelty is percentage of molecules that are valid, unique, not identical to seed, and novel
- Sampling radius empirically determined to maximize effective novelty
- CDDD used as baseline model – trained with molecular property loss
- Perceiver BART sampling speed improved relative to MegaMolBART
- MolVAE and MolMIM show significant improvements in validity and effective novelty

Model	Latent Dim	Validity (%)	Uniqueness (%)	Novelty (%)	Effective Novelty (%)	Test Runtime
MegaMolBART	Variable	75.0	84.8	94.2	51.1	8.7 hours
Perceiver BART	2048	71.8	94.9	94.6	59.1	38 min
MolVAE	2048	95.7	100.0	98.1	93.9	64 min
MolMIM	512	98.7	100.0	95.5	94.2	30 min
CDDD	512	84.5	98.9	99.5	82.2	12 hours [†]

[†]CDDD decoding speed limited by batch size.

Single Property Optimization with CMA-ES

Model	QED (%)	Penalized logP	
	$\delta \geq 0.4$	$\delta \geq 0.4$	$\delta \geq 0.6$
AtomG2G	73.6	-	-
HeirG2G	76.9	-	-
DESMILES	77.8	-	-
QMO	92.8	7.71 ± 5.65	3.73 ± 2.85
MolGrow	-	8.34 ± 6.85	4.06 ± 5.61
GraphAF	-	8.21 ± 6.51	4.98 ± 6.49
GraphDF	-	9.19 ± 6.43	4.51 ± 5.80
CDGS	-	9.56 ± 6.33	5.10 ± 5.80
FaST	-	18.09 ± 8.72	8.98 ± 6.31
MolMIM	94.6	28.45 ± 54.67	7.60 ± 23.62
MolMIM		$9.44 \pm 4.12^\dagger$	$4.57 \pm 3.87^\dagger$

- Performed optimization of QED or penalized logP with query budget of 50,000 oracle calls per input molecule
- Success is % of molecules with QED ≥ 0.9 or penalized logP improvement while maintaining Tanimoto similarity $\delta \geq \{0.4, 0.6\}$
- MolMIM achieves the highest QED and logP success rates
- Penalized logP results impacted by known exploit where identical functional groups are repeatedly added

Results above solid bar as in B. Chen, X. Fu, R. Barzilay, T. Jaakkola, ArXiv (2021) and S. C. Hoffman, *et al*, Nat Mach Intell. 4, 21–31 (2022)

QED and logP oracles from Therapeutic Data Commons.

[†]logP improvement limited to ≤ 20

Single Property Optimization with CMA-ES

Model	QED (%)	Penalized logP	
	$\delta \geq 0.4$	$\delta \geq 0.4$	$\delta \geq 0.6$
AtomG2G	73.6	-	-
HeirG2G	76.9	-	-
DESMILES	77.8	-	-
QMO	92.8	7.71 \pm 5.65	3.73 \pm 2.85
MolGrow	-	8.34 \pm 6.85	4.06 \pm 5.61
GraphAF	-	8.21 \pm 6.51	4.98 \pm 6.49
GraphDF	-	9.19 \pm 6.43	4.51 \pm 5.80
CDGS	-	9.56 \pm 6.33	5.10 \pm 5.80
FaST	-	18.09 \pm 8.72	8.98 \pm 6.31
MolMIM	94.6	28.45 \pm 54.67	7.60 \pm 23.62
MolMIM		9.44 \pm 4.12 [†]	4.57 \pm 3.87 [†]

- Performed optimization of QED or penalized logP with query budget of 50,000 oracle calls per input molecule
- Success is % of molecules with QED ≥ 0.9 or penalized logP improvement while maintaining Tanimoto similarity $\delta \geq \{0.4, 0.6\}$
- MolMIM achieves the highest QED and logP success rates
- Penalized logP results impacted by known exploit where identical functional groups are repeatedly added
- Recall: MolMIM trained without chemical properties, activity, or fragment knowledge


Results above solid bar as in B. Chen, X. Fu, R. Barzilay, T. Jaakkola, ArXiv (2021) and S. C. Hoffman, *et al*, Nat Mach Intell. 4, 21–31 (2022)

QED and logP oracles from Therapeutic Data Commons.


[†]logP improvement limited to ≤ 20

A Clustered Latent Space with Mutual Information Machine

- Same architecture as VAE, but loss maximizes mutual information and minimizes marginal entropy
- MIM results in an informative and clustered latent space



$$\begin{aligned}
 \mathcal{L}_{\text{A-MIM}}(\theta) &= \frac{1}{2} \left(CE(\mathcal{M}_S^q(\mathbf{x}, \mathbf{z}), q_\theta(\mathbf{x}, \mathbf{z})) \right. \\
 &\quad \left. + CE(\mathcal{M}_S^q(\mathbf{x}, \mathbf{z}), p_\theta(\mathbf{x}, \mathbf{z})) \right) \\
 &\geq H_{\mathcal{M}_S^q}(\mathbf{x}) + H_{\mathcal{M}_S^q}(\mathbf{z}) - I_{\mathcal{M}_S^q}(\mathbf{x}; \mathbf{z})
 \end{aligned}$$



Model	QED (%) $\delta \geq 0.4$	Penalized logP $\delta \geq 0.4$	$\delta \geq 0.6$
JT-VAE	8.8	1.03 \pm 1.39	0.28 \pm 0.79
GCPN	9.4	2.49 \pm 1.30	0.79 \pm 0.63
MolDQN	-	3.37 \pm 1.62	1.86 \pm 1.21
MMPA	32.9	-	-
VSeq2Seq	58.5	3.37 \pm 1.75	2.33 \pm 1.17
VJTNN+GAN	60.6	-	-
VJTNN	-	3.55 \pm 1.67	2.33 \pm 1.24
MoFlow	-	4.71 \pm 4.55	2.10 \pm 2.86
GA	-	5.93 \pm 1.41	3.44 \pm 1.09
AtomG2G	73.6	-	-
HeirG2G	76.9	-	-
DESMILES	77.8	-	-
QMO	92.8	7.71 \pm 5.65	3.73 \pm 2.85
MolGrow	-	8.34 \pm 6.85	4.06 \pm 5.61
GraphAF	-	8.21 \pm 6.51	4.98 \pm 6.49
GraphDF	-	9.19 \pm 6.43	4.51 \pm 5.80
CDGS	-	9.56 \pm 6.33	5.10 \pm 5.80
FaST	-	18.09 \pm 8.72	8.98 \pm 6.31
MolMIM	94.6	28.45 \pm 54.67	7.60 \pm 23.62
MolMIM		9.44 \pm 4.12 [†]	4.57 \pm 3.87 [†]

gle Property Optimization

- Repeated QED and penalized logP optimization with query budget of 50,000 oracle calls per input molecule
- Success is % of molecules with QED ≥ 0.9 or penalized logP improvement while maintaining Tanimoto similarity $\delta \geq \{0.4, 0.6\}$
- MolMIM achieves the highest QED and logP success rates
- Penalized logP results impacted by known exploit where identical functional groups are repeatedly added
- MolMIM results were repeated with logP improvement limited

Results above solid bar as in B. Chen, X. Fu, R. Barzilay, T. Jaakkola, ArXiv (2021) and S. C. Hoffman, *et al*, Nat Mach Intell. 4, 21–31 (2022).

[†]logP improvement limited to ≤ 20

Perspective on BioNeMo

- Models have a finite lifespan, the value is in the learnings
- Developing and productizing internal research is useful for driving improvements to the platform
- Scalability and acceleration are differentiating factors
- Surface NVIDIA technologies, and use bottlenecks to drive the development software and hardware improvements